Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05737706 · ClinicalTrials.gov registry record · Phase 1
Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
A Phase 1 study, sponsored by Mirati Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
NCT05737706 is a Phase 1 study that was terminated before completion, run by Mirati Therapeutics. The registered enrollment target is 63 participants.
The verdict
NCT05737706, a Phase 1 study, was terminated before completion, sponsored by Mirati Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
Study Summary
A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.
Interventions
- DRUG MRTX1133
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2025-03-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05737706
The ClinicalTrials.gov registry entry for NCT05737706 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirati Therapeutics, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MRTX1133 is the first listed.
NCT05737706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05737706 about?
NCT05737706 is a clinical study titled "Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation". A Phase 1/2 study of MRTX1133 in solid tumors harboring a KRAS G12D mutation.
What is the current status of trial NCT05737706?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2023-03-06. Estimated completion is 2025-03-10.
What interventions are being tested in trial NCT05737706?
The interventions under investigation include: MRTX1133 (DRUG).
Who is sponsoring clinical trial NCT05737706?
This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.